NASDAQ:LIXT - Nasdaq - US5393193017 - Common Stock - Currency: USD
1.2701
-0.09 (-6.61%)
The current stock price of LIXT is 1.2701 USD. In the past month the price decreased by -48.16%. In the past year, price decreased by -42.79%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The firm encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The company is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.
LIXTE BIOTECHNOLOGY HOLDINGS
No. 2, 248 Route 25A
East Setauket NEW YORK 11733 US
CEO: John S. Kovach
Employees: 4
Company Website: https://lixte.com/
Investor Relations: http://ir.lixte.com
Phone: 13102032902
The current stock price of LIXT is 1.2701 USD. The price decreased by -6.61% in the last trading session.
The exchange symbol of LIXTE BIOTECHNOLOGY HOLDINGS is LIXT and it is listed on the Nasdaq exchange.
LIXT stock is listed on the Nasdaq exchange.
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) has a market capitalization of 2.86M USD. This makes LIXT a Nano Cap stock.
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) currently has 4 employees.
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) has a resistance level at 2.45. Check the full technical report for a detailed analysis of LIXT support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LIXT does not pay a dividend.
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) will report earnings on 2025-03-17.
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.78).
The outstanding short interest for LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) is 4.32% of its float. Check the ownership tab for more information on the LIXT short interest.
ChartMill assigns a fundamental rating of 2 / 10 to LIXT. LIXT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months LIXT reported a non-GAAP Earnings per Share(EPS) of -1.78. The EPS increased by 45.98% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -235.9% | ||
ROE | -292.66% | ||
Debt/Equity | 0 |